title: Interstitial granulomatous dermatitis associated with darifenacin.
abstract: Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.
authors.affiliation: Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
authors.forename: Holly R
authors.initials: HR
authors.lastname: Mason
authors.forename: Jil K
authors.initials: JK
authors.lastname: Swanson
authors.forename: Jonhan
authors.initials: J
authors.lastname: Ho
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Patton
mesh_terms: D001572:Benzofurans / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006099:Granuloma / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D011759:Pyrrolidines / Q000009:adverse effects* / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy
chemical_list: D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; C101207:darifenacin